Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.71 and traded as high as $0.9746. Brainstorm Cell Therapeutics shares last traded at $0.93, with a volume of 3,838 shares trading hands.
Brainstorm Cell Therapeutics Price Performance
The company’s 50 day simple moving average is $0.77 and its 200 day simple moving average is $0.71. The company has a market capitalization of $10.26 million, a PE ratio of -0.28 and a beta of 0.30.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
